Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Rita Gambaro

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Recenti Progressi in Medicina|June 16, 2026
Maria Silvia Cona, Anna Rita Gambaro, Matteo De Monte, et al.
Clinical Breast Cancer|April 4, 2017
Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical TrialsAntonio Bernardo, Raffaella Palumbo, Rebecca Pedersini, et al.
Therapeutic Advances in Medical Oncology|April 2, 2021
Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian studyRaffaella Palumbo, Rosalba Torrisi, Federico Sottotetti, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2019
ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary studyBeatrice De Troia, Davide Dalu, Virginio Filipazzi, et al.
Breast Cancer Research and Treatment|August 28, 2021
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)Rosalba Torrisi, Raffaella Palumbo, Rita De Sanctis, et al.
Gynecologic Oncology|March 22, 2024
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activityAnna Passarelli, Vittoria Carbone, Sandro Pignata, et al.
BMC Medicine|November 22, 2019
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trialMaria Vittoria Dieci, Giancarlo Bisagni, Alba A Brandes, et al.
Frontiers in Oncology|June 1, 2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from <i>CaRe</i>, a multicentric, observational studyFrancesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Recenti Progressi in Medicina|June 16, 2026
Maria Silvia Cona, Anna Rita Gambaro, Matteo De Monte, et al.
Clinical Breast Cancer|April 4, 2017
Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical TrialsAntonio Bernardo, Raffaella Palumbo, Rebecca Pedersini, et al.
Therapeutic Advances in Medical Oncology|April 2, 2021
Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian studyRaffaella Palumbo, Rosalba Torrisi, Federico Sottotetti, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2019
ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary studyBeatrice De Troia, Davide Dalu, Virginio Filipazzi, et al.
Breast Cancer Research and Treatment|August 28, 2021
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)Rosalba Torrisi, Raffaella Palumbo, Rita De Sanctis, et al.
Gynecologic Oncology|March 22, 2024
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activityAnna Passarelli, Vittoria Carbone, Sandro Pignata, et al.
BMC Medicine|November 22, 2019
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trialMaria Vittoria Dieci, Giancarlo Bisagni, Alba A Brandes, et al.
Frontiers in Oncology|June 1, 2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from <i>CaRe</i>, a multicentric, observational studyFrancesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, et al.
Pageof 1